Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000941:Antigens; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000276:immunology; D002175:Candida; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000188:drug therapy; D007166:Immunosuppressive Agents; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000276:immunology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009109:Mumps virus; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D009578:Nitrobenzenes; D010051:Ovarian Neoplasms / Q000276:immunology; D012882:Skin Tests; D014373:Tuberculin; D002583:Uterine Cervical Neoplasms / Q000276:immunology; D014747:Vinblastine / Q000627:therapeutic use
D000941:Antigens; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D009578:Nitrobenzenes; D014373:Tuberculin; D003609:Dactinomycin; D014747:Vinblastine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate